Companies

Alliance is a specialty pharmaceutical company based in the United Kingdom. The company has a strong track record of acquiring the rights to established niche brands and owns or shares the rights to 34 branded prescribed pharmaceutical products. Revenues in the year ending December 2006 were £17.3 million, an increase of 19.7% over the 12 months to December 2005. Like for like growth was 7.7% with the additional growth derived from brands acquired in the period.

Alliance maintains strategic and controlling functions with a management team possessing large pharmaceutical company experience. More capital intensive functions are outsourced to maximise efficiency and profitability.

The core of Alliances' activities have been in the United Kingdom and the Republic of Ireland. However recent acquisitions have enabled an international expansion to growing markets.

Alliance has acquired brands from leading pharmaceutical companies such as Novartis, Procter and Gamble, Lilly and Pfizer. Alliance is constantly considering a number of in-licensing opportunities. At this stage we will look at possibilities in all therapy areas.

If you are seeking a UK and Europe market entry partner, Alliance's sales, marketing and regulatory expertise can help you navigate the whole process from marketing authorisation submission to field force deployment. Alliance will expand infrastructure to fit the opportunity.

Alliance has two products in development: Posidorm is an unqiue formulation of melatonin for sleep disorders and Isprelor is a 25mcg formulation of misoprostol specially developed for induction of labour. We are interested in discussions with potential co-development and out-licensing partners.

Alliance focuses on prescription branded medicines in the human medical and dental sectors, primarily in the UK and Ireland with progressive and considered development into selective international markets.

We have a number of clear business strategies for growth:

1. Acquisition of established brands for continued commercial success (with a focus on Rx brands).
2. UK and European market entry partner for novel in-licensed technologies and therapies
3. Expanded international marketing of acquired technologies and therapies
4. Selected development of products for co-development and out-licensing